EUCTR2009-017978-21-BG进行中（未招募）1 期
Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE) - PREMIERE Registry
Merck Serono S.A. - Geneva0 个研究点目标入组 2,175 人开始时间: 2015年9月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •The registry target population includes all subjects who participated in Sponsor oral cladribine Phase I to III clinical trials in MS associated with a protocol approved prior to the time of submission of the marketing application and completed (last patient, last visit) after November 2008. This corresponds to five clinical trials (protocols number 25643, 26593, 27820, 27967 and 28821) and 2175 subjects.
- •All subjects in the target population will be eligible for enrollment in the registry once their participation in the clinical trial has ended. The following inclusion criteria must be fulfilled:
- •Prior enrollment into selected clinical trials, regardless of randomization to either IMP or placebo, once participation in the clinical trial or in the clinical trial extension has ended
- •Written informed consent is given
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2159
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •The following reasons will exclude subjects from registry participation:
- •Subjects who cannot be reached by phone;
- •Subjects who are unable to answer the registry questionnaires and who do not have a next of kin or caregiver available to answer the registry questionnaires;
- •Subjects who – either during the lag interval or subsequently – enter an interventional study.
研究者
相似试验
进行中（未招募）
1 期
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trialsMultiple Sclerosis patients who have participated in cladribine tablets clinical trialsMedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2009-017978-21-SEMerck Serono S.A. - Geneva1,148
进行中（未招募）
1 期
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trialsMultiple Sclerosis patients who have participated in cladribine tablets clinical trialsMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017978-21-ITMERCK SERONO SA1,148
进行中（未招募）
1 期
Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE) - PREMIERE RegistryEUCTR2009-017978-21-PTMerck Serono S.A. - Geneva1,148
进行中（未招募）
1 期
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trialsEUCTR2009-017978-21-GBMerck Serono S.A. - Geneva1,148
进行中（未招募）
1 期
Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE) - PREMIERE RegistryMultiple Sclerosis patients who have participated in cladribine tablets clinical trialsMedDRA version: 17.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017978-21-PLMerck Serono S.A. - Geneva1,148